Palliative Benefits of the Multimodality Approach in the Re-treatment of Recurrent Malignant Glioma: Two Case Reports

Two young male patients treated seven and four years back, for malignant glioma, returned with recurrence at the same site, with a World Health Organization (WHO) Performance Score of four and two. Both underwent resurgery and received postoperative reirradiation of 5040 cGy in 28 fractions and conc...

Descripción completa

Detalles Bibliográficos
Autores principales: TR, Arulponni, MG, Janaki, S, Nirmala
Formato: Texto
Lenguaje:English
Publicado: Medknow Publications 2009
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902119/
https://www.ncbi.nlm.nih.gov/pubmed/20668597
http://dx.doi.org/10.4103/0973-1075.58464
Descripción
Sumario:Two young male patients treated seven and four years back, for malignant glioma, returned with recurrence at the same site, with a World Health Organization (WHO) Performance Score of four and two. Both underwent resurgery and received postoperative reirradiation of 5040 cGy in 28 fractions and concurrent Temozolomide 75 mg/m(2) body surface area (BSA) daily, and one patient received additional adjuvant Temozolomide 250 mg (150 mg/m(2) BSA). Both patients tolerated the treatment well with 16 and 14 months follow-up from the time of recurrence. They were symptom-free, with normal physical function and good mental state, and resumed their respective jobs.

Ejemplares similares